{"id":3714,"date":"2014-01-27T14:14:28","date_gmt":"2014-01-27T14:14:28","guid":{"rendered":"\/?p=3714"},"modified":"2014-01-27T14:14:38","modified_gmt":"2014-01-27T14:14:38","slug":"easton-pharmaceuticals-inc-otcmktseaph-ends-week-on-a-high-note","status":"publish","type":"post","link":"\/articles\/easton-pharmaceuticals-inc-otcmktseaph-ends-week-on-a-high-note\/","title":{"rendered":"Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) Ends Week on a High Note"},"content":{"rendered":"

Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH<\/a>) rounded off the week with a successful run in the last two trading days. On Friday, EAPH<\/a> added a further 20% to $0.0154, on buying volumes of $1.33 million, a bit subdued compared to Thursday’s spike. EAPH<\/a> is boosted by expectations of this week’s investors’ conference in Washington, DC, and we will have to see if the event has a direct event on the market, or if last week already consumed the news. \"EAPH2701.png\" <\/p>\n

EAPH<\/a> has not seen a new promotion since January 8th, but has been taken up in another round of enthusiasm surrounding two categories of tickers: pharmaceutical companies and cannabis stocks. Thus, EAPH<\/a> enjoys the short-term confidence of investors’ forums, with expectations that the run will continue for a while longer. At least for Monday, the expectations are for an extremely successful trading session of further gains. \"GRNH2701.png\"<\/p>\n

The company has a relatively lower number of shares outstanding, which also helps those who decide to hold on for a while longer. With around 244 million shares, and a further 250 million authorized, EAPH<\/a> is for now not overly diluted, at least for a pink sheet company. As for the financials, while not dismal, they show that EAPH<\/a> is still miles away from being a robust money-maker with its chosen business model:<\/p>\n